Key points from article :
Sarcopenia trial shows no evidence of toxicity or safety issues and patients were enrolled in the next higher dose of MYMD-1.
MyMD Pharmaceuticals, Inc.® announced further advancement of Phase 2 clinical trial of lead drug candidate MYMD-1® as a therapy for delaying aging and expanding healthy lifespan.
The trial’s Safety Review Committee has confirmed no safety issues and no toxicity in the prior cohort.
The study investigates the efficacy, tolerability and pharmacokinetics of MYMD-1 in the treatment of chronic inflammation associated with sarcopenia in participants aged 65 years or older.
“Having already demonstrated the drug’s mechanism of action and efficacy in Phase 1 ... expect efficacy data in the second half of 2022", said Chris Chapman, Chief Medical Officer.
TNF-α blockers are the most prescribed drugs by revenue, a global market of approximately $40 billion per year.
NOTE: the multivariate model graph included in the press release appears to be misleading according to Matt Kaeberlein in this Twitter thread where he compares it to the actual survival curve data.
